115035-47-7 Usage
Uses
Used in Pharmaceutical Industry:
Glycine, N-[(1,1-dimethylethoxy)carbonyl]-L-alanylglycyl(9CI) is used as a building block for the synthesis of complex peptides and proteins for various therapeutic applications. Its unique structure allows for the creation of novel compounds with specific biological activities, contributing to the development of new drugs and treatments.
Used in Biochemical Research:
In the field of biochemical research, Glycine, N-[(1,1-dimethylethoxy)carbonyl]-L-alanylglycyl(9CI) serves as a valuable tool for studying the structure, function, and interactions of peptides and proteins. Its incorporation into experimental designs can provide insights into the mechanisms of protein folding, stability, and interactions with other biomolecules.
Used in Drug Development:
Glycine, N-[(1,1-dimethylethoxy)carbonyl]-L-alanylglycyl(9CI) is utilized in drug development as a potential therapeutic agent or as a component of drug delivery systems. Its specific structure may offer targeted actions or improved pharmacokinetic properties, enhancing the efficacy and safety of medications.
Used in Peptide Synthesis:
In the synthesis of peptides, Glycine, N-[(1,1-dimethylethoxy)carbonyl]-L-alanylglycyl(9CI) acts as a key intermediate, enabling the creation of peptides with tailored properties. Its use in peptide synthesis can lead to the development of bioactive peptides for various applications, including as therapeutic agents, diagnostic tools, or research reagents.
Check Digit Verification of cas no
The CAS Registry Mumber 115035-47-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,5,0,3 and 5 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 115035-47:
(8*1)+(7*1)+(6*5)+(5*0)+(4*3)+(3*5)+(2*4)+(1*7)=87
87 % 10 = 7
So 115035-47-7 is a valid CAS Registry Number.
115035-47-7Relevant academic research and scientific papers
Synthesis of a novel esterase-sensitive cyclic prodrug of a hexapeptide using an (acyloxy)alkoxy promoiety
Gangwar, Sanjeev,Pauletti, Giovanni M.,Siahaan, Teruna J.,Stella, Valentino J.,Borchardt, Ronald T.
, p. 1356 - 1362 (2007/10/03)
Synthetic methodology for preparing novel esterase-sensitive cyclic prodrugs of peptides with increased protease stability and cell membrane permeability compared to linear peptides is described. Cyclic prodrug 1 of the hexapeptide H-Trp-Ala-Gly-Gly-Asp-Ala-OH linked by the N-terminal amino group to the C-terminal carboxyl group via an (acyloxy)alkoxy promoiety was synthesized. A convergent synthetic approach involving Boc[[(alaninyloxy)methyl]carbonyl]-N-tryptophan (2) and H-Ala-Gly-Gly-Asp(OBzl)-OTce (3) was used. The key fragment 2 has the promoiety inserted between the Ala and the Trp residues. Fragment 3 was synthesized by a solution-phase approach using standard Boc-amino acid chemistry. These fragments were coupled to produce the protected linear hexapeptide, which after deprotection was cyclized using standard high-dilution techniques to yield cyclic prodrug 1. In pH 7.4 buffer (HBSS) at 37°C, cyclic prodrug 1 was shown to degrade quantitatively to the hexapeptide (t( 1/4 ) = 206 ± 11 min). The rate of hydrolysis of cyclic prodrug 1 was significantly faster in human blood (t( 1/4 ) = 132 ± 4 min) than in HBSS. Paraoxon, a known inhibitor of esterases, slowed this hydrolysis of cyclic prodrug 1 to a value (t( 1/4 ) = 198 ± 9 min) comparable to the chemical stability. In human blood, cyclic prodrug 1 was shown to be 25-fold more stable than the linear hexapeptide.
